INOTREM
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In paral... lel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.
INOTREM
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2013-03-08
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.inotrem.com
Total Employee:
11+
Status:
Active
Total Funding:
121 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Arima Genomics
Arima Genomics is a biotechnology company that develops solutions to drive genomics discovery.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
ITeos Therapeutics
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
VectivBio
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Debt Financing - Inotrem
Kreos Capital
Kreos Capital investment in Debt Financing - Inotrem
Bpifrance
Bpifrance investment in Debt Financing - Inotrem
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series B - Inotrem
Sofinnova Partners
Sofinnova Partners investment in Series B - Inotrem
Invus
Invus investment in Series B - Inotrem
Morningside Venture Investments
Morningside Venture Investments investment in Series B - Inotrem
Andera Partners
Andera Partners investment in Series B - Inotrem
BioMed Invest
BioMed Invest investment in Series B - Inotrem
Andera Partners
Andera Partners investment in Series A - Inotrem
Key Employee Changes
| Date | New article |
|---|---|
| 2021-03-24 | Inotrem Bolsters Leadership Team With the Appointment of Sven Zimmermann as New CEO |
Official Site Inspections
http://www.inotrem.com
- Host name: cluster014.ovh.net
- IP address: 213.186.33.87
- Location: Saran France
- Latitude: 47.9531
- Longitude: 1.871
- Timezone: Europe/Paris
- Postal: 45770
More informations about "Inotrem"
Inotrem - Control Innate Immunity
A novel approach to target inflammatory diseases A novel approach to target inflammatory diseases Inotrem is an advanced clinical stage biotechnology company specialized in …See details»
Company Overview - Inotrem
Leveraging its proprietary technology platform, Inotrem is also conducting a broad monoclonal antibody program to target chronic inflammation, fibrotic diseases and immuno-oncology. Inotrem’s deep knowledge of the TREM-1 pathway biology …See details»
Inotrem - Crunchbase Company Profile & Funding
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation …See details»
Leadership Team - Inotrem
• Co-founder and CEO of Inotrem from 2014 to April 2021 • Head of Pharma Research and Early Development at Roche (2010 to 2012) • Head of Development and Chief Medical Officer at …See details»
Inotrem - Funding, Financials, Valuation & Investors - Crunchbase
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. New. Resources. Advanced Search. ... How much funding …See details»
Inotrem - Company Profile & Staff Directory - ContactOut
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology …See details»
Inotrem 2025 Company Profile: Valuation, Funding & Investors
Inotrem General Information Description. Developer of novel therapeutics designed to treat inflammatory diseases. The company's therapeutics focus on targeted immunotherapy for …See details»
Inotrem Company Profile - Office Locations, Competitors ... - Craft
Inotrem is a biotech company specializing in the discovery and development of novel treatments in the field of inflammatory pathologies with a focus on critical care. The company's leading …See details»
Inotrem - Portfolio Company Profile, Executives and Private Equity …
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. See Inotrem's complete profile, including its private equity …See details»
Inotrem - VentureRadar
Inotrem is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation …See details»
Inotrem - Contacts, Employees, Board Members, Advisors & Alumni
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. ... Experience the new Crunchbase, powered by AI . …See details»
Inotrem Receives Funding From the Crohn’s & Colitis ... - Fintech …
Jan 10, 2023 “We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology …See details»
Inotrem SA - Drug pipelines, Patents, Clinical trials - Synapse
Last update 08 Mar 2025. Inotrem SA. Holding Company |See details»
Inotrem company information, funding & investors | La French …
Inotrem, biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases. Here you'll find information about their funding, …See details»
Inotrem Company Profile: Overview and Full News Analysis
Inotrem received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program . After initial support in December 2022, continuation of …See details»
Inotrem, The French Biotech Firm Fighting Sepsis, COVID-19 And …
Nov 2, 2021 Founded in 2013, Inotrem is working on groundbreaking immunotherapies against life-threatening inflammatory syndromes. Backed by European and North American investors, …See details»
News & Events - Inotrem
Paris (France), January 8. 2024. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, today …See details»
Motrem by Inotrem for Septic Shock: Likelihood of Approval
Dec 4, 2024 Inotrem is a biopharmaceutical company that discovers and develops drugs for treating sepsis and septic shock. The company’s pipeline portfolio comprise of Phase I stage …See details»
Inotrem Receives Funding From the Crohn’s & Colitis Foundation
Jan 9, 2023 “We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology …See details»
Inotrem looks to regulatory agencies after COVID treatment hits …
Oct 25, 2022 The phase 2 study evaluated Inotrem’s nangibotide, a peptide designed to inhibit TREM-1—which are receptors on certain white blood cells—among ventilated COVID-19 …See details»